Alternative Complement Pathway Signature Determines Immunosuppression and Resistance to Immunotherapy Plus Tyrosine Kinase Inhibitor Combinations in Renal Cell Carcinoma

Jiajun Wang,Sihong Zhang,Ying Wang,Yanjun Zhu,Xianglai Xu,Jianming Guo

Urologic Oncology: Seminars and Original Investigations（2023）

引用 6|浏览10

暂无评分

摘要

•Alternative complement pathway signature (ACPS) was a biomarker for TKI+IO therapy.•ACPS predicted TKI+IO benefit vs. TKI monotherapy.•ACPS was associated with exhausted T cell infiltration and immunosuppression.

查看译文

关键词

Renal cell carcinoma,Complement,Immunosuppression,Immune checkpoint inhibitor,Tyrosine kinase inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要